Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapy
- PMID: 27542257
- PMCID: PMC5308654
- DOI: 10.18632/oncotarget.11348
Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapy
Abstract
Hepatitis C virus (HCV) can replicate in peripheral blood mononuclear cells (PBMCs), which can produce interferon to defend against virus infection. We hypothesized that dynamic gene expression in PBMCs might impact the treatment efficacy of peginterferon/ribavirin in HCV patients. PBMCs were collected at baseline, 1st week and 4th week of treatment from 27 chronic HCV-1 patients with 48-week peginterferon/ribavirin therapy (screening dataset n = 7; validation dataset n = 20). A sustained virologic response (SVR) was defined as undetectable HCV RNA throughout the 24 weeks after end-of-treatment. A complete early virologic response (cEVR) was defined as negative HCV RNA at treatment week 12. Forty-three differentially expressed genes identified by Affymetrix microarray were validated by quantitative polymerase chain reaction. Thirteen genes at week 1 and 24 genes at week 4 were upregulated in the SVR group compared with the non-SVR group. We selected 8 target genes (RSAD2, LOC26010, HERC5, HERC6, IFI44, SERPING1, IFITM3, and DDX60) at week 1 as the major components of the predictive model. This predictive model reliably stratified the responders and non-responders at week 1 (AUC = 0.89, p = 0.007 for SVR; AUC = 0.95, p = 0.003 for cEVR), especially among patients carrying the IL28B rs8099917 TT genotype (AUC = 0.89, p = 0.02 for SVR; AUC = 1.0, p = 0.008 for cEVR). The performance of this predictive model was superior to traditional predictors, including the rapid virologic response, viral load and IL28B genotype.
Keywords: hepatitis C; interferon; sustained virologic response.
Conflict of interest statement
None of the authors have potential conflicts of interest related to the manuscript.
Figures



Similar articles
-
Interferon-stimulated genes are associated with peginterferon/ribavirin treatment response regardless of IL28B alleles in hepatitis C virus/HIV-coinfected patients.AIDS. 2013 Mar 13;27(5):687-96. doi: 10.1097/QAD.0b013e32835ce2c1. AIDS. 2013. PMID: 23196939
-
Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response.J Gastroenterol Hepatol. 2010 Apr;25(4):758-65. doi: 10.1111/j.1440-1746.2009.06148.x. J Gastroenterol Hepatol. 2010. PMID: 20492331
-
Peripheral blood mononuclear cells microRNA predicts treatment outcome of hepatitis C virus genotype 1 infection.Antiviral Res. 2014 May;105:135-42. doi: 10.1016/j.antiviral.2014.03.003. Epub 2014 Mar 15. Antiviral Res. 2014. PMID: 24637254
-
Prediction of sustained virologic response based on week 4 and week 12 response in hepatitis C virus genotype 1 patients treated with peginterferon and ribavirin: assessment in a favorable IL28B allele-prevalent area.Intervirology. 2013;56(3):178-83. doi: 10.1159/000345539. Epub 2013 Jan 9. Intervirology. 2013. PMID: 23306941
-
Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.Liver Transpl. 2008 Jan;14(1):53-8. doi: 10.1002/lt.21312. Liver Transpl. 2008. PMID: 18161839
Cited by
-
HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients.J Biomed Sci. 2021 Mar 30;28(1):23. doi: 10.1186/s12929-021-00718-6. J Biomed Sci. 2021. PMID: 33785040 Free PMC article.
-
Proteome profiling in the aorta and kidney of type 1 diabetic rats.PLoS One. 2017 Nov 9;12(11):e0187752. doi: 10.1371/journal.pone.0187752. eCollection 2017. PLoS One. 2017. PMID: 29121074 Free PMC article.
-
Changes in renal function indices in cirrhotic chronic hepatitis C patients treated with sofosbuvir-containing regimens.Oncotarget. 2017 Jun 28;8(53):90916-90924. doi: 10.18632/oncotarget.18701. eCollection 2017 Oct 31. Oncotarget. 2017. PMID: 29207613 Free PMC article.
References
-
- Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41–52. - PubMed
-
- Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005;42:962–973. - PubMed
-
- Yu ML, Chuang WL, Chen SC, Dai CY, Hou C, Wang JH, Lu SN, Huang JF, Lin ZY, Hsieh MY, Tsai JF, Wang LY, Chang WY. Changing prevalence of hepatitis C virus genotypes: molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan. J Med Virol. 2001;65:58–65. - PubMed
-
- National Institutes of Health Consensus Development Conference Statement Management of hepatitis C: 2002-June 10–12 2002. Hepatology. 2002;36:S3–20. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous